$CRSP News Article - Vertex and CRISPR Therapeutics Present New Data in 22 Patients With Greater Than 3 Months Follow-Up Post-Treatment With Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001(TM) at European Hematology Association Annual Meeting https://marketwirenews.com/news-releases/vert...40117.html